Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.
Acknowledgment of Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Medical Crossfire®: Multidisciplinary Case-Based Discussions – Optimizing Diagnosis and Treatment of IBS-C and CIC
Release Date: November 30, 2020
Expiration Date: November 30, 2021
Activity Overview
Medical Crossfire®, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This lively discussion will help place new developments into clinical context to help you optimize care for your patients with these disorders.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This online educational activity is directed toward primary care physicians, gynecologists, gastroenterologists, nurse practitioners, physician assistants, and primary care physicians. Additional health care professionals who are involved in the care of patients with IBS-C/CIC will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the epidemiology, pathophysiology, and burden of IBS-C and CIC
- Assess clinical presentation and diagnosis of IBS-C and CIC
- Evaluate the efficacy and safety data of current and emerging therapies in the care of patients with IBS-C and CIC
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
Chief, Gastroenterology, Hepatology, and Nutrition
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School at UTHealth
Director, Ertan Digestive Disease Center
Memorial Hermann Hospital, Texas Medical Center
Houston, TX
Disclosures: Consultant: AbbVie, Salix Pharmaceuticals, Alfasigma USA, Takeda; Speakers Bureau: AbbVie, Salix Pharmaceuticals, Alfasigma USA, Takeda.
Associate Professor of Medicine and Surgery
Irene D. Pritzker Foundation Research Scholar
Director, Neurogastro Motility and Functional Bowel Programs
Director, Motts Tonelli GI Physiology Lab
Feinberg School of Medicine
Northwestern University
Chicago, IL
Disclosures: Consultant and Speakers Bureau: Arena Pharmaceuticals, Alfasigma USA, Bayer Healthcare, Allergan (AbbVie), Ironwood Pharmaceuticals, Salix Pharmaceuticals, Takeda, Alnylam Pharmaceuticals; Other: Unrestricted gift for research from the Irene D. Pritzker Foundation.
Assistant Professor, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Maia Kayal, MD, has no relevant financial relationships with commercial interests to disclose.
Health Sciences Clinical Professor
Department of Family Medicine
Associate Dean, Culture and Community Education
Director, UC Irvine Program in Medical Education for the Latino Community
UC Irvine School of Medicine
University of California, Irvine
Irvine, CA
Disclosures: Charles Vega, MD, FAAFP, has no relevant financial relationships with commercial interests to disclose.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
.jpg "PER")
